← 治験一覧に戻る
18歳以上の男女を対象に、デュピルマブ注射とプラセボを比較した慢性単純性苔癬の掻痒改善効果を調査する研究（STYLE 1）
基本情報
- NCT ID
- NCT06687967
- ステータス
- 実施中（募集終了）
- 試験のフェーズ
- 第3相
- 試験タイプ
- 介入
- 目標被験者数
- 142
- 治験依頼者名
- Sanofi
概要
This is a parallel, Phase 3, 2-arm study for treatment. The purpose of this study is to measure improvement in pruritus with dupilumab subcutaneous injections compared with placebo injections in male and female participants aged at least 18 years with LSC. Study details include: The study duration will be up to 40 weeks. The treatment duration will be up to 24 weeks. The follow-up duration after treatment will be 12 weeks. The number of visits will be 6.
対象疾患
Lichen Simplex Chronicus
介入
Dupilumab(DRUG)
Placebo(DRUG)